MX2021011154A - Compositions and methods for treating androgen receptor positive forms of cancer. - Google Patents

Compositions and methods for treating androgen receptor positive forms of cancer.

Info

Publication number
MX2021011154A
MX2021011154A MX2021011154A MX2021011154A MX2021011154A MX 2021011154 A MX2021011154 A MX 2021011154A MX 2021011154 A MX2021011154 A MX 2021011154A MX 2021011154 A MX2021011154 A MX 2021011154A MX 2021011154 A MX2021011154 A MX 2021011154A
Authority
MX
Mexico
Prior art keywords
cancer
androgen receptor
compositions
receptor positive
methods
Prior art date
Application number
MX2021011154A
Other languages
Spanish (es)
Inventor
Anna Ericsson
Maureen Caligiuri
Sylvie Guichard
Qunli Xu
Original Assignee
Forma Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2019/039936 external-priority patent/WO2020006483A1/en
Application filed by Forma Therapeutics Inc filed Critical Forma Therapeutics Inc
Publication of MX2021011154A publication Critical patent/MX2021011154A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

Pharmaceutical compositions comprising a CBP Inhibitor compound can be used to treat patients diagnosed with Androgen Receptor positive forms of cancer, such as mCRPC and TNBC, including patients diagnosed with the AR-v7 splice form.
MX2021011154A 2019-03-15 2020-03-13 Compositions and methods for treating androgen receptor positive forms of cancer. MX2021011154A (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201962819490P 2019-03-15 2019-03-15
US201962819487P 2019-03-15 2019-03-15
US201962819476P 2019-03-15 2019-03-15
US201962819472P 2019-03-15 2019-03-15
US201962819482P 2019-03-15 2019-03-15
US201962821660P 2019-03-21 2019-03-21
PCT/US2019/039936 WO2020006483A1 (en) 2018-06-29 2019-06-28 Inhibiting creb binding protein (cbp)
PCT/US2020/022823 WO2020190792A1 (en) 2019-03-15 2020-03-13 Compositions and methods for treating androgen receptor positive forms of cancer

Publications (1)

Publication Number Publication Date
MX2021011154A true MX2021011154A (en) 2021-10-22

Family

ID=72521203

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011154A MX2021011154A (en) 2019-03-15 2020-03-13 Compositions and methods for treating androgen receptor positive forms of cancer.

Country Status (7)

Country Link
EP (1) EP3938365A4 (en)
CN (1) CN113784967A (en)
AU (1) AU2020241709A1 (en)
BR (1) BR112021018266A2 (en)
CA (1) CA3132995A1 (en)
MX (1) MX2021011154A (en)
WO (1) WO2020190792A1 (en)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010110380A1 (en) * 2009-03-27 2010-09-30 興和株式会社 Fused piperidine compound and pharmaceutical agent comprising same
AU2011258217B2 (en) * 2010-05-26 2016-12-15 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
MX370535B (en) * 2013-11-18 2019-12-17 Forma Therapeutics Inc Tetrahydroquinoline compositions as bet bromodomain inhibitors.
EP3224258B1 (en) * 2014-11-27 2019-08-14 Genentech, Inc. 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
WO2017197056A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
EP3681885B1 (en) * 2017-09-15 2024-02-28 Forma Therapeutics, Inc. Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors
WO2020006483A1 (en) * 2018-06-29 2020-01-02 Forma Therapeutics, Inc. Inhibiting creb binding protein (cbp)

Also Published As

Publication number Publication date
CA3132995A1 (en) 2020-09-24
WO2020190792A1 (en) 2020-09-24
EP3938365A4 (en) 2023-01-25
CN113784967A (en) 2021-12-10
EP3938365A1 (en) 2022-01-19
BR112021018266A2 (en) 2022-02-01
AU2020241709A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
WO2019222112A8 (en) Mcl-1 inhibitors
JOP20220008A1 (en) Parp1 inhibitors
PH12020551244A1 (en) Pd-1/pd-l1 inhibitors
GEP20237506B (en) Pcsk9 antagonist compounds
PH12019502132A1 (en) Combination therapy for the treatment or prevention of tumours
MX2019008207A (en) Methods of treating cancer with anti-pd-1 antibodies.
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
PH12020552214A1 (en) Ectonucleotidase inhibitors and methods of use thereof
MX2021010252A (en) Inhibitors of glucocorticoid receptor.
MX2019011506A (en) Combinations of chk1- and wee1 - inhibitors.
PH12016502352A1 (en) Pharmaceutical composition
TW201613578A (en) Pharmaceutical combinations
MX2022001004A (en) Enzyme inhibitors.
MX370586B (en) Imidazolyl tricyclic enones as antioxidant iflammation modulators.
ZA202106519B (en) Caspase inhibitors and methods of use thereof
MX2021011154A (en) Compositions and methods for treating androgen receptor positive forms of cancer.
MX2021011699A (en) Quinoline derivatives and their use for the treatment of cancer.
MX2020013805A (en) Pyridopyrimidinone derivatives for use as axl inhibitors.
MX2020010156A (en) Cdp protein secretion inhibitors.
MX2019003368A (en) Anti-cancer agents and preparation thereof.
TW202417457A (en) Mcl-1 inhibitors
CR20220255A (en) Egfr inhibitors
MX2022000781A (en) C17 polar-substituted heteroaromatic synthetic triterpenoids and methods of use thereof.
EA202092539A1 (en) NLRP3 MODULATORS
EA202091694A1 (en) PD-1 / PD-L1 INHIBITORS